From @morgans analyst, Scott Power Just back from the World Diabetes Conference in Melbourne. Globally the prevalence of type 2 diabetes and obesity has reached epidemic proportions and the treatment of these diseases represents two of the largest and fastest growing healthcare challenges in the world. Yet despite the desperate need for effective clinical solutions, doctors have very few options that can safely and effectively treat both diseases simultaneously. One treatment in the early stage of adoption is GI Dynamics' EndoBarrier, which is the first endoscopically delivered device therapy for obese patients with type 2 diabetes. I heard from one of the surgeons experienced in treating patients as well as a patient who received the device 7 months ago. Although in early stages of adoption it is clear the momentum is building quickly both from the patient and doctors perspective. GID presented additional compelling clinical data further validating the device.
The Livewire Equities feed brings you a range of insights that relate to Australian equities
No areas of expertise